Biohaven Ltd
Company Profile
Business description
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Contact
c/o Biohaven Pharmaceuticals, Inc
215 Church Street
New HavenCT06510
USAT: +1 203 404-0410
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
274
Stocks News & Analysis
stocks
ASX healthcare share undervalued post earnings
stocks
ASX energy share sees 363% increase in dividend
stocks
Wide moat share remains cheap despite rising costs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,338.80 | 54.50 | -0.58% |
| CAC 40 | 8,478.57 | 39.37 | 0.47% |
| DAX 40 | 26,324.35 | 58.21 | 0.22% |
| Dow JONES (US) | 53,577.40 | 160.24 | 0.30% |
| FTSE 100 | 10,876.36 | 9.80 | -0.09% |
| HKSE | 25,652.97 | 141.87 | 0.56% |
| NASDAQ | 26,151.30 | 171.11 | 0.66% |
| Nikkei 225 | 66,262.16 | 405.73 | 0.62% |
| NZX 50 Index | 14,013.21 | 20.49 | 0.15% |
| S&P 500 | 7,677.28 | 24.42 | 0.32% |
| S&P/ASX 200 | 9,127.80 | 55.90 | -0.61% |
| SSE Composite Index | 3,912.52 | 23.08 | 0.59% |